Clinical Trial

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 4 locations 2026-05-27
Trial Details
NCT Number NCT07235202
Lead Sponsor Shenzhen Majory Biotechnology Co., Ltd.
Conditions Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 45 participants
Start Date 2025-12-24
Primary Completion 2028-06-22 (estimated)
Study Completion 2028-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-05-26